Oral Answers to Questions

Kit Malthouse Excerpts

Wednesday 26th March 2025 Commons Chamber

[Feryal Clark]

I pay tribute to my hon. Friend for drawing attention to the work of the Mark Sommerville Foundation in this important area. Government funders are investing in MND research to accelerate progress. Let me give just one example. Through UK Research and Innovation and the National Institute for Health and Care Research, the Government are investing £6 million in the MND translational accelerator, led by Dementias Platform UK. The aim of the funded projects is to accelerate the development of treatment for MND.

[Kit Malthouse (North West Hampshire) (Con)]

It is good to hear that there is continuing investment in the search for therapies and indeed cures to deal with this horrific disease, but even if therapies do emerge, one of the frustrations in getting them to patients may be the inability of scientists to obtain access to clinical trials. In “Life Sciences Vision”, published in 2021, a number of groups combined to look into access to clinical trials in the UK and the possibility of increasing the number of such trials, but acceleration has not been good. I chair the all-party parliamentary group for life sciences, and one of the comments I hear most frequently in the industry is about the need for a more focused effort in this regard. Would the Minister consider establishing a clinical trials taskforce in her Department to drive this important work forward?